Foghorn Therapeutics Inc
FHTX
NASDAQ
Biotechnology
$6.26
USD
-0.23 (-3.54%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $385.41M
Volume 140.0K
Revenue
$36.74M
TTM
+52.0%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-64.58M
TTM
+14.3%
YoY
Operating Cash Flow
$-84.24M
TTM
+6.9%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 7.6 | 8.2 | 9.2 | 3.3 | 16.1 |
YoY Growth | +9.7% | +4.4% | +223.8% | -45.1% | +112.7% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 7.6 | 8.2 | 9.2 | 3.3 | 16.1 |
Selling, General & Administrative | 6.9 | 6.7 | 6.8 | 6.6 | 6.4 |
Other Operating Expenses | 0.0 | 0.0 | 4.3 | 0.0 | 0.0 |
Total Operating Expenses | 28.7 | 26.7 | 33.1 | 24.8 | 24.9 |
Operating Income | -21.1 | -18.5 | -23.9 | -21.6 | -8.8 |
EBITDA | -20.2 | -17.6 | -17.2 | -21.3 | -8.6 |
Other Income / Expense | 0.9 | 0.6 | 0.5 | -0.0 | 0.0 |
Total Other Income / Expense | 3.2 | 2.7 | 2.2 | 1.7 | 1.6 |
Income Before Income Taxes | -17.9 | -15.8 | -21.7 | -19.9 | -7.2 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -17.9 | -15.8 | -21.7 | -19.9 | -7.2 |
Consolidated Net Income / Loss | -17.9 | -15.8 | -21.7 | -19.9 | -7.2 |
Net Income Attributable to Common Shareholders | -17.9 | -15.8 | -21.7 | -19.9 | -7.2 |
Basic EPS | -$0.28 | -$0.25 | -$0.34 | -$0.29 | -$0.10 |
Diluted EPS | -$0.28 | -$0.25 | -$0.34 | -$0.29 | -$0.10 |
Basic Shares Outstanding | 63.0M | 63.0M | 63.1M | 69.5M | 70.6M |
Diluted Shares Outstanding | 63.0M | 63.0M | 63.1M | 69.5M | 70.6M |